BRM421 not checked

BRIM Biotechnology Inc. · BRM424

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Dry Eye Disease (DED), Keratoconjunctivitis Sicca
Main trialPhase 2
“To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)”In the company’s words, NCT07078955 on ClinicalTrials.gov
Other names
BRM424

Other drugs for Dry Eye Disease (DED)

All 44 drugs for Dry Eye Disease (DED)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Nov 2026 A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Phase 3Completed 30 Dec 2023 Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
Phase 2/3Completed 23 Jun 2020 Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
Phase 2Completed 20 May 2017 Safety and Efficacy of BRM421 for Dry Eye Syndrome
Phase 2Unknown 30 Aug 2025 Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BRM421

Following is part of Solo: you see every change to BRM421 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in